- Our Story
- Our Products
- Our Science
- Our People & Citizenship
-
Investors
- Reports and Filings
- Presentations & Earnings Calls
-
Shares
- Share Price
- Stock Updates
- Equity & Dividend History
- Unpaid & Unclaimed Dividend
- Analyst Coverage
- Shareholding Pattern
- Share Transfer Information
- Buyback
- Details of Shares for transfer to IEPF May 2018
- Notice pursuant to IEPF Rules, May 2018
- Details of Shares for transfer to IEPF May 2019
- Notice Pursuant to IEPF Rules, May 2019
- Details of Shares for transfer to IEPF May 2020
- Notice pursuant to IEPF Rules, May 2020
- Details of Shares for transfer to IEPF May 2021
- Notice pursuant to IEPF Rules, May 2021
- Governance
- Investor Services
-
ESG profile
- Media
- Partners
- Contact Us
Press Releases
Dec
- Dr. Reddy's Laboratories announces the launch of Melphalan Hydrochloride for Injection in the U.S. Market
- Dr. Reddy’s announces it has reached a settlement with the US Government regarding company’s compliance with the Consumer Product Safety Act
- Dr. Reddy’s Announces Approval of Impoyz™ (clobetasol propionate) Cream, 0.025% First-Cycle NDA Approval
Nov
Sep
- Dr. Reddy's Laboratories announces the launch of Sevelamer Carbonate Tablets in the U.S. Market
- Dr. Reddy’s Laboratories announces the launch of Metaxalone Tablets, USP in the U.S Market
- Dr. Reddy’s Laboratories announces the launch of Bupropion Hydrochloride Extended - Release Tablets, USP (XL) In the U.S Market
Aug
Jul
Jun
May
Apr
Mar
Feb
